homefeedbacksupportlog on 20-Nov-2008 
  Search
 
   
 
  Browse
ALL OF BIOLOGY

Pharmacology & Drug Discovery
Antimicrobial Agents
Cancer Therapeutics
Cardiovascular Pharmacology
Drug Discovery & Design
Endocrine & Metabolic Pharmacology
Gastrointestinal Pharmacology
Genito-Urinary & Reproductive Pharmacology
Immunopharmacology & Hematologic Pharmacology
Molecular Pharmacology
Musculoskeletal & Dermatologic Pharmacology
Neuropharmacology & Psychopharmacology
Pharmacogenomics
Pharmacokinetics & Drug Delivery
Renal Pharmacology
Respiratory Pharmacology
Toxicology
Related Sections
Bioinformatics
Biomacromolecule-Ligand Interactions
Cell Signalling
Cell Signalling & Trafficking Structures
Chemical Biology of the Cell
Directed Molecular Evolution
Genomics
Macromolecular Chemistry
Medical Genetics
Physiogenomics
Protein Chemistry & Proteomics
Small Molecule Chemistry

profile subject selected for My F1000 Biology

Browse > Pharmacology & Drug Discovery > Cancer Therapeutics
Top 10 / All time Top 10 / Most viewed / Hidden jewels		Page 1 of 36. Select Page: 1 2 3 4 5 6 7 8 9 10 >>
Display 10 / 20 / 50 papers per page

printer friendly 
to email [Help]

Must Read
F1000 Factor 6.0

Tech Advance
Novel Drug Target
 Chemical control of protein stability and function in living mice.
Banaszynski LA, Sellmyer MA, …, Wandless TJ, Thorne SH
Nat Med 2008 Oct 14(10):1123-7 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Ken Irvine with Yongqiang Feng
Evaluated 20 Nov 2008

Must Read
F1000 Factor 6.0

New Finding
 Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma.
Montero J, Morales A, …, Colell A, Fernández-Checa JC
Cancer Res 2008 Jul 1 68(13):5246-56 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | David Andrews
Evaluated 19 Nov 2008

Must Read
F1000 Factor 6.0

Hypothesis
New Finding
 Glucose induces an autocrine activation of the Wnt/beta-catenin pathway in macrophage cell lines.
Anagnostou SH, Shepherd PR
Biochem J 2008 Dec 1 416(2):211-8 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Alex Toker
Evaluated 18 Nov 2008

Recommended
F1000 Factor 3.0

New Finding
 Structure-activity relationships study of bastadin 6, an anti-angiogenic brominated-tyrosine derived metabolite from marine sponge.
Kotoku N, Hiramatsu A, …, Aoki S, Kobayashi M
Arch Pharm (Weinheim) 2008 Sep 341(9):568-77 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Tadeusz Molinski
Evaluated 18 Nov 2008

Must Read
F1000 Factor 6.0

Confirmation
Tech Advance
Novel Drug Target
 Design and synthesis of highly sensitive fluorogenic substrates for glutathione S-transferase and application for activity imaging in living cells.
Fujikawa Y, Urano Y, …, Inoue H, Nagano T
J Am Chem Soc 2008 Nov 5 130(44):14533-43 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Hening Lin
Evaluated 17 Nov 2008

Must Read
F1000 Factor 6.0

New Finding
Novel Drug Target
 Pharmacological targeting of NF-kappaB potentiates the effect of the topoisomerase inhibitor CPT-11 on colon cancer cells.
Lagadec P, Griessinger E, …, Dreano M, Peyron JF
Br J Cancer 2008 Jan 29 98(2):335-44 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Jean Clairambault
Evaluated 14 Nov 2008

Must Read
F1000 Factor 6.0

New Finding
Novel Drug Target
 Rac activation and inactivation control plasticity of tumor cell movement.
Sanz-Moreno V, Gadea G, …, Sahai E, Marshall CJ
Cell 2008 Oct 31 135(3):510-23 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Richard Klemke
Evaluated 13 Nov 2008

Recommended
F1000 Factor 3.0

New Finding
 TAp73 knockout shows genomic instability with infertility and tumor suppressor functions.
Tomasini R, Tsuchihara K, …, Jurisicova A, Mak TW
Genes Dev 2008 Oct 1 22(19):2677-91 [abstract on PubMed] [related articles] [FREE full text]
Selected by | Rong Li with Giulia Rancati
Evaluated 12 Nov 2008

Recommended
F1000 Factor 3.2

New Finding
Tech Advance
Novel Drug Target
 Engineering microRNA responsiveness to decrease virus pathogenicity.
Kelly EJ, Hadac EM, Greiner S, Russell SJ
Nat Med 2008 Nov 14(11):1278-83 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | James Crowe / Lynne Maquat with Olaf Isken
First evaluation 12 Nov 2008 | Latest evaluation 19 Nov 2008

Must Read
F1000 Factor 6.0

New Finding
Novel Drug Target
 T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance.
Pesu M, Watford WT, …, Creemers J, O'Shea JJ
Nature 2008 Sep 11 455(7210):246-50 [abstract on PubMed] [related articles] [full text] [order article]
Selected by | Robert Fuller
Evaluated 10 Nov 2008


top of pagePage 1 of 36. Select Page: 1 2 3 4 5 6 7 8 9 10 >>
Display 10 / 20 / 50 papers per page

© 1999-2008 Biology Reports Ltd unless otherwise stated. < info@f1000.com >   Terms and conditions   Legal info